{'fraction_non_alphanumeric': 0.026246719160104987, 'fraction_numerical': 0.01706036745406824, 'mean_word_length': 5.027667984189724, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF® Therapeutic Vaccine

Cervical 
uterine cancer represents the fourth most common malignant neoplasm worldwide 
in the female sex in terms of incidence, principally from epithelial origen. The high expression of EGFR in this 
tumor leads to the search for therapeutic alternatives. An Expanded Access 
Clinical Program was carried out in parallel groups, randomized, multicenter 
and prospective study, to evaluate the survival of patients with advanced 
cervical carcinoma, without therapeutic alternative, who would be treated with 
the therapeutic vaccine CIMAvax-EGF®, the humanized mAb nimotuzumab or the combination of both products, which targeted EGF and EGFR 
respectively. The patients were included between 2008 and 2010 with a more than five years follow-up. The results 
show that the serious adverse events related to the experimental treatments 
were 0.9%; 1.1% and 2.6% and a median ITT survival of 9.1, 23.5, and 16.3 months for 
CIMAvax-EGF®, nimotuzumab and the combination of both, respectively. Thus fulfilling the hypothesis of safety 
and efficacy proposed in the investigation was achieved. The three therapeutic 
regimens achieved overall survival rates greater than 35% at 60 months, 
encouraging results for advanced uterine cervical cancer. A phase III clinical 
trial is proposed to consolidate these results in a greater number of patients 
with nimotuzumab as study drug.